CIP
AQST icon

Chartwell Investment Partners’s Aquestive Therapeutics AQST Stock Holding History

Chartwell Investment Partners’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$535K Buy
+107,550
New +$419K 0.02% 396

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

Chartwell Investment Partners's AQST Position: Q3 2024 in Review

Chartwell Investment Partners opened a new position in Aquestive Therapeutics (AQST) in Q3 2024: 107,550 shares worth $535K. The stake represents 0.02% of the portfolio and ranks #396 among its holdings.

117 funds tracked by Wall St. Rank hold AQST as of Q3 2024.

  • Chartwell Investment Partners held 107,550 shares of Aquestive Therapeutics worth $535K as of Q3 2024.
  • Aquestive Therapeutics was a new Chartwell Investment Partners position in Q3 2024.
  • Aquestive Therapeutics made up 0.02% of Chartwell Investment Partners's portfolio in Q3 2024, its #396 holding.
  • 117 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2024.

Based on Chartwell Investment Partners's 13F filing for Q3 2024, filed 4 Nov 2024.